Back to top

Image: Bigstock

Avantor, Inc. (AVTR) Hits 52-Week High, Can the Run Continue?

Read MoreHide Full Article

Have you been paying attention to shares of Avantor (AVTR - Free Report) ? Shares have been on the move with the stock up 19.2% over the past month. The stock hit a new 52-week high of $33.54 in the previous session. Avantor has gained 17.9% since the start of the year compared to the 1.8% move for the Zacks Medical sector and the 2.2% return for the Zacks Medical Services industry.

What's Driving the Outperformance?

The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on February 3, 2021, Avantor, Inc. reported EPS of $0.29 versus consensus estimate of $0.26 while it beat the consensus revenue estimate by 0.14%.

For the current fiscal year, Avantor, Inc. is expected to post earnings of $1.17 per share on $6.96 billion in revenues. This represents a 31.46% change in EPS on an 8.79% change in revenues. For the next fiscal year, the company is expected to earn $1.33 per share on $7.31 billion in revenues. This represents a year-over-year change of 13.68% and 5.12%, respectively.

Valuation Metrics

Avantor, Inc. may be at a 52-week high right now, but what might the future hold for the stock? A key aspect of this question is taking a look at valuation metrics in order to determine if the company has run ahead of itself.

On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). These styles are represented by grades running from A to F in the categories of Value, Growth, and Momentum, while there is a combined VGM Score as well. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.

Avantor, Inc. has a Value Score of C. The stock's Growth and Momentum Scores are B and C, respectively, giving the company a VGM Score of B.

In terms of its value breakdown, the stock currently trades at 28.3X current fiscal year EPS estimates. On a trailing cash flow basis, the stock currently trades at 19.4X versus its peer group's average of 23.2X. Additionally, the stock has a PEG ratio of 1.07. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.

Zacks Rank

We also need to consider the stock's Zacks Rank, as this supersedes any trend on the style score front. Fortunately, Avantor, Inc. currently has a Zacks Rank of #2 (Buy) thanks to rising earnings estimates.

Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Avantor, Inc. meets the list of requirements. Thus, it seems as though Avantor, Inc. shares could have potential in the weeks and months to come.

How Does Avantor, Inc. Stack Up to the Competition?

Shares of Avantor, Inc. have been moving higher, and the company still appears to be a decent choice, but what about the rest of the industry? Some of its industry peers are also impressive, including EUROFINS SCIENT (ERFSF - Free Report) , BIOMERIEUX (BMXMF - Free Report) , and HCA Healthcare (HCA - Free Report) , all of which currently have a Zacks Rank of at least #2 and a VGM Score of at least B, making them well-rounded choices.

However, it is worth noting that the Zacks Industry Rank for this group is in the bottom half of the ranking, so it isn't all good news for Avantor, Inc. Still, the fundamentals for Avantor, Inc. are promising, and it still has potential despite being at a 52-week high.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Avantor, Inc. (AVTR) - free report >>

HCA Healthcare, Inc. (HCA) - free report >>

EUROFINS SCIENT (ERFSF) - free report >>

BIOMERIEUX (BMXMF) - free report >>

Published in